辅助放疗对不同年龄组乳腺恶性叶状肿瘤患者总生存和乳腺癌特异性生存的影响:基于SEER的回顾性观察研究
该研究基于SEER数据库2000至2020年纳入2261例女性乳腺恶性叶状肿瘤患者,其中455例(20.12%)接受放疗、1806例(79.88%)未接受放疗,按年龄分为18-45、46-55、56-65和66-80岁四组。倾向性评分匹配后各年龄组总生存和乳腺癌特异性生存均无差异,多因素Cox回归显示放疗不影响长期生存。
要点
- SEER回顾性纳入2261例乳腺恶性叶状肿瘤女性患者,455例(20.12%)接受辅助放疗。
- 倾向性评分匹配后各年龄组放疗与未放疗的总生存和乳腺癌特异性生存均无差异。
- 多因素Cox回归显示放疗不影响乳腺恶性叶状肿瘤患者的长期生存。
核心结论
- 没有证据表明特定年龄组的乳腺恶性叶状肿瘤患者可从辅助放疗中获得长期生存获益。
研究设计与样本
- 回顾性观察研究,从SEER数据库选取2000至2020年女性乳腺恶性叶状肿瘤患者。
- 共纳入2261例患者,其中455例(20.12%)接受放疗、1806例(79.88%)未接受放疗。
- 按年龄分为18-45、46-55、56-65和66-80岁四组,采用Kaplan-Meier生存分析、单因素和多因素Cox回归及倾向性评分匹配。
主要发现
- 匹配前,18-45岁组放疗与未放疗的总生存P=0.019、乳腺癌特异性生存P=0.016,46-55岁组总生存P<0.001、乳腺癌特异性生存P<0.001,差异有统计学意义。
- 匹配后,18-45岁组总生存P=0.473、乳腺癌特异性生存P=0.750,46-55岁组总生存P=0.380、乳腺癌特异性生存P=0.816,56-65岁组总生存P=0.484、乳腺癌特异性生存P=0.290,66-80岁组总生存P=0.997、乳腺癌特异性生存P=0.763,均无差异。
- 多因素Cox回归分析中,放疗不影响乳腺恶性叶状肿瘤患者的长期生存。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Malignant phyllodes tumor of the breast (MPTB) is a rare type of breast cancer, with an incidence of less than 1%. The value of adjuvant radiotherapy (RT) for MPTB has been controversial. The aim of the study was to explore the effect of radiotherapy on the long-term survival of female patients with MPTB at different ages. METHODS: Female MPTB patients were selected from the Surveillance, Epidemiology, and End Results (SEER) database between 2000 and 2020. A Kaplan-Meier survival analysis was conducted to investigate the value of RT for the long-term survival of MPTB patients in different age groups. Additionally, univariate and multivariate Cox regression analyses were performed for overall survival (OS) and breast cancer-specific survival (BCSS) of MPTB patients. Furthermore, propensity score matching (PSM) was also performed to balance the differences in baseline characteristics. RESULTS: 2261 MPTB patients were included in this study, including 455 patients (20.12%) with RT and 1806 patients (79.88%) without RT. These patients were divided into four cohorts based on their ages: 18-45, 46-55, 56-65, and 65-80. Before adjustment, there was a statistically significant difference in long-term survival between RT-treated and non-RT-treated patients in the younger age groups (age group of 18-45 years: OS P = 0.019, BCSS P = 0.016; age group of 46-55 years: OS P < 0.001, BCSS P < 0.001). After PSM, no difference was found in long-term survival of patients in both younger and older groups regardless of whether they received RT (age group of 18-45 years: OS P = 0.473, BCSS P = 0.750; age group of 46-55 years: OS P = 0.380, BCSS P = 0.816, age group of 56-65 years: OS P = 0.484, BCSS P = 0.290; age group of 66-80 years: OS P = 0.997, BCSS P = 0.763). In multivariate COX regression analysis, RT did not affect long-term survival in patients with MPTB. CONCLUSION: There is no evidence that long-term survival of MPTB patients in specific age groups can benefit from RT.
引用
- Yang P, Zhang G, Zhang Y, et al. Effect of adjuvant radiotherapy on overall survival and breast cancer-specific survival of patients with malignant phyllodes tumor of the breast in different age groups: a retrospective observational study based on SEER. Radiat Oncol. 2024. PMID: 38773616. doi:10.1186/s13014-024-02442-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。